Alembic Pharmaceuticals receives final approval for Olmesartan Medoxomil Tablets & Medoxomil with Hydrochlorothiazide Tablets
From USFDA
Alembic Pharmaceuticals has received USFDA final approval for Olmesartan Medoxomil Tablets, 5mg, 20mg and 40mg and Olmesartan Medoxomil with Hydrochlorothiazide Tablets 20/12.5 mg, 40/12.5 mg and 40/25 mg. The approved ANDAs are indicated for the treatment of hypertension.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content